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Abstract
Costs of neurogenic bladder vary widely and depend on a number of factors including severity of 
disease, symptomatology, patient insurance, and devices required. Recognition of how each 
treatment strategy will impact the patient financially could help guide selection of treatment as 
well as improve compliance with the chosen regimen. We have attempted to provide an overview 
of long term cost considerations for the neurogenic bladder patient. Armed with this information, 
the practitioner can better help the patient select a bladder care regimen that balances the desire to 
both minimize symptoms now and preserve urinary tract integrity for the future, yet still remain 
cost effective.
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INTRODUCTION
Neurogenic bladder is characterized by damage to the central nervous system (CNS), 
autonomic nervous system (ANS), or sympathetic nervous system (SNS) and can result in 
the inability of the patient to store urine (urinary frequency, urgency, or incontinence) or 
fully empty the bladder on command (urinary retention)1•. It presents a long-term challenge 
for both the patient and the physician and has the potential of amassing significant long-term 
costs. Some causes include multiple sclerosis (MS), spinal cord injury (SCI), traumatic brain 
injury (TBI), cerebrovascular accident (CVA), spina bifida, cerebral palsy, transverse 
myelitis, and diabetes mellitus (DM) 2. Because of variability in hospital charges and 
insurance billing, it can often be challenging for the patient and physician to accurately 
predict the lifetime costs of this condition. Fortunately, many of the same symptoms 
affecting neurogenic bladder patients affect non-neurogenic overactive bladder patients as 
well, making it possible to extrapolate cost data from non-neurogenic overactive bladder 
studies when making estimates.
Please direct all correspondence to: CR Powell, MD, Indiana University School of Medicine, Department of Urology, 535 Barnhill 
Dr., Suite 420, Indianapolis, IN 46202, phone: 317 944-4622, fax: 317 944-0174 crpowell@iupui.edu. 
Compliance with Ethics Guideline
Conflict of Interest C. Flack: none; C.R. Powell: none.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
HHS Public Access
Author manuscript
Curr Bladder Dysfunct Rep. Author manuscript; available in PMC 2016 December 01.
Published in final edited form as:









Surgical intervention for neurogenic bladder (continent or incontinent diversion, 
augmentation, sling, or artificial sphincter placement, for example) carries a cost that is 
certainly a major contributor to the global cost of neurogenic bladder to the medical system 
and to society, but it can be argued that surgical intervention has the potential to cure 
incontinence, possibly resulting in a net cost savings. However, because the bulk of the costs 
of surgery often lie with insurance companies, governments, or with the hospital (when bills 
are not paid), these interventions don't necessarily represent long-term tangible costs to the 
individual. Often more apparent to the patient and family are the ongoing direct costs related 
to supplies needed to stay dry (pads, diapers, liners) and to empty fully (catheters, drainage 
supplies, and lubricant). With this chronic condition the patient will also require close 
surveillance and consistent care in an effort to avoid the common complications of a 
neurogenic bladder, namely urinary tract infections (UTI), stones, pressure ulcers, and high 
storage pressures leading to renal damage. Surveillance for these complications will remain 
necessary throughout the patient's life3•, amassing office copays, laboratory tests, and 
urinary tract imaging in addition to time lost from work. Each of these aspects impacts cost 
and should be considered when selecting a treatment plan. Some have suggested that 
shifting responsibility for cost savings to physicians could save costs at the grassroots level, 
but may also potentially compromise the patient-doctor relationship, traditionally 
understood as the doctor always advocating for the patient's best interest.4 It is important to 
keep this in mind when analyzing cost containment in healthcare.
Behavior Training
Behavior training is first line therapy for patients with non-neurogenic OAB according to the 
2012 AUA Guidelines document 5. When considering neurogenic bladder, there is less 
evidence and the benefit is not as clear, leading the authors of the European Guidelines on 
Neurogenic Lower Urinary Tract Dysfunction to conclude it “may be useful”. Some of this 
is based on evidence that it is specifically helpful in patients suffering from MS 3, 6•. 
Compared with daily medication or surgery, behavior training has an obvious cost benefit 
once the patient has completed supervised therapy, but studies investigating efficacy are 
lacking. This may be due to the hypothesis that behavior therapy and biofeedback therapy 
utilize the body's neural pathways to effect lasting change, and these are altered in the 
neurogenic bladder.
Devices/Disposables For Urinary Retention
Many patients with neurogenic bladder have difficulty fully emptying the bladder and the 
preferred management is intermittent self-catheterization performed by the patient or a 
caregiver.7•• In their review of best practices in catheterization, Newman et al. find that 
intermittent catheterization leads to fewer complications and infections than placement of an 
indwelling catheter.7•• Choice of approach to intermittent catheterization has substantial 
impact on long-term costs of neurogenic bladder. The number of catheterizations required 
per day will vary from patient to patient, based on liquid intake, bladder compliance, 
presence of reflux and renal function, but a general “rule of thumb” is to catheterize 
frequently enough to maintain a maximum bladder volume of 500mL.8 To do so, patients 
typically will require a 12-14 French catheter 4-6 times per day.9 Patients may choose to 
perform clean or aseptic intermittent catheterization. Clean catheterization allows for the 
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reuse of catheters.10 Although this method of catheterization is not endorsed on the 
packaging and is considered off-label use in the USA,7, 11 this has become an often-used 
strategy for limiting the cost of supplies. Long term costs of this strategy then depend on 
how many times the catheter is reused before disposal, as well as the lubricant needed for 
each use. Recent studies show that about half of United States patients (56%) who perform 
intermittent catheterization reuse their catheters, and many experts encourage this practice in 
low income areas and in developing countries where economic constraints limit the 
availability of these devices.7•• Choice of cleaning method (soap and water, microwave 
sterilization, etc...) there have been no published randomized controlled trials that compare 
either cost or efficacy of sterilization and reuse.7•• Aseptic technique, in contrast, involves 
kits that provide sterile gloves and catheters that either come as a self-contained 
prelubricated kit or whose hydrophilic coating becomes a lubricant when wet.10 In order to 
be considered aseptic technique, these catheters are single use only and one study found at 
the single use requirement of aseptic technique had the biggest impact on cost. The authors 
report single use catheter technique costs approximately £28 /$46/ €36.4 per week10. 
Multiple use catheterization is far cheaper, costing approximately £0.5 /$1/€0.8 per catheter 
plus the cost of lubricant.10 One innovative strategy discussed in the literature is volume 
dependent intermittent catheterization (VDIC). This technique reduces the number of 
catheters used by reducing the frequency of intermittent catheterization by postponing 
catheterization if bladder volume falls below a pre-determined “threshold volume”. This 
measurement is done by bladder ultrasound. The authors were able to realize a 46% 
reduction in cost with no obvious adverse effects 12.
Costs of Urinary Tract Infections
Also contributing to the cost of neurogenic bladder and intermittent catheterization are 
urinary tract infections (UTIs), which necessitate clinic visits, testing, antibiotic treatment, 
and at times hospitalization. Urinary tract infections are one of the most common side 
effects of neurogenic bladder and they often result from clean intermittent 
catheterization.7, 10•• Retained urine, introduction of foreign bacteria into the urinary tract, 
and breaks in the bladder urothelium and urethral lining all increase the risk of infection.7•• 
A number of variations in clean intermittent catheterization (CIC) technique have been 
advocated, however an abridged Cochrane Review of catheterization techniques found no 
convincing evidence that incidence of asymptomatic urinary tract infection was affected by 
catheterization technique (aseptic versus clean), type of catheter (coated, uncoated, single-
use, multiple-use), or self-catheterization versus catheterization by a caregiver.8 Trials 
comparing single use (sterile) catheter versus multiple use (clean) catheter found no 
significant difference in incidence of symptomatic UTI or weeks to onset of UTI.10 
Furthermore, another study found that fewer antibiotic prescriptions were needed for those 
performing sterile catheterization , costing 43% less than the cost for those utilizing cleaned, 
reused catheters and non-sterile technique. Yet because the sterile kits were so costly the 
total cost of performing sterile catheterization was 277% of those using non sterile 
technique.13 In order to predict the expected costs for a particular patient, it can be helpful to 
consider those characteristics that contribute to a higher frequency of urinary tract 
infections: higher catheterization volumes (resulting from infrequent catheterizations or 
increased fluid intake), female gender (women report more UTIs than men), catheterization 
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by a caregiver (non-self catheterization), business of lifestyle, and mobility impairment.7•• 
Furthermore, it has been noted that the longer the time frame that an individual catheterizes, 
the higher the incidence of UTI.14
Devices/Disposables For Urinary Incontinence
For those neurogenic bladder patients who experience incontinence, a number of 
incontinence devices are available, each with variable cost and availability. A 2007 
Cochrane review15 compares the cost and efficacy of four kinds of incontinence devices: 
disposable inserts, disposable menstrual pads , washable pants with an integrated washable 
inserts, and washable inserts. This review found that while leakage protection was best using 
disposable inserts designed for incontinence, disposable menstrual pads were the cheapest 
option and that although disposable inserts were the preferred option for many women, 
disposable menstrual pads were acceptable in some situations due to their decreased cost. 
This review recommended that the practitioner work with the patient to choose. Ultimately, 
patients may opt to use all kinds of incontinence devices in order to obtain optimum 
continence when necessary but take advantage of less costly options when possible. Many 
experts advocate this technique since there is no clear benefit to skin health for any of the 
above mentioned incontinence devices and freedom of choice has been shown to improve 
patient satisfaction.15
When discussing incontinence products, costs for neurogenic bladder may be similar to 
those of overactive bladder (OAB). In five European countries (Germany, Italy, Spain, 
Sweden, and the United Kingdom), investigators noted the average annual direct costs of 
OAB (not necessarily neurogenic bladder) ranged from €269 to €706 per patient per year. 
The largest contributor to cost was the use of incontinence pads, which would likely be true 
for neurogenic bladder patients as well, and was attributed to 63% of the annual per patient 
cost of OAB. On a larger scale, the cost to health care systems for all five countries was 
estimated at €4.2 billion in 2000 16.
Cost of Procedural Intervention
Some have suggested that procedural intervention may save costs related to disposables and 
catheters, which are very visible to the patient, but very few studies have been published to 
prove this claim. Further complicating matters, it is difficult to discern cost savings versus 
cost shifting – which may falsely support the choice of one versus the other based on cost. 
For example, During the 1990s, outpatient spending for overactive bladder rose dramatically 
compared to operative costs. Looking closely, however, this was not inherently due to one 
treatment modality being more expensive than the other, but rather because a shift in costs 
occurred from inpatient procedures to procedures not requiring hospitalization as advances 
were made in outpatient treatment.17 One form of procedural intervention, 
OnabotulinumtoxinA, was studied in the widely quoted ABC trial to examine the hypothesis 
that there may be a difference in effectiveness between onabotulinum toxin therapy over a 6 
month period and a comparable anticholinergic. Although the investigators found no 
difference in the reduction in incontinence episodes (−1.6 vs. −1.7), there was a significant 
difference in the number of patients reporting “cure” by the study criteria (27% vs. 13%, 
respectively, p=0.003).18 One team of investigators found that onabotulinumtoxinA (BoNT-
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A) used to treat refractory neurogenic detrusor overactivity from SCI or MS was more 
effective than “best supportive care” alone, adding 0.4 Quality Adjusted Life years (QALY), 
at an increased cost of £1,689 over 5 years 19•. The authors felt this was cost effective, but 
leave the question unanswered regarding how much the system should be willing to pay for 
one additional QALY. Another study compared cost estimates and effectiveness (based on 
QUALY gained) of sacral nerve stimulation versus BoNT-A, finding cost of sacral nerve 
stimulation to be greater ($15,743 versus $4,392) but that it was also marginally more 
effective (1.73 versus 1.63 QALYs).20 Another study projected 10-year costs of BoNT-A. 
They found that costs increased in a specialist setting versus non-specialist setting, and costs 
increased proportional to baseline comorbidity. Patients requiring more than 4 
catheterizations per day had a significantly higher 10 year projected cost. Additionally, 
when comparing 10-year costs of BoNT-A to 10-year costs of clam cystoplasty, they found 
that costs were the same or lower for BoNT-A injections where the symptoms responded to 
the injections. However, if urgency, frequency, and incontinence remained severe enough to 
require 4 or more catheterization episodes per day cystoplasty was the less costly choice.21
System Wide Cost of Urinary Incontinence
Urinary incontinence is a common symptom of neurogenic bladder. In the USA, 
investigators estimated the annual direct costs for urinary incontinence in 2007 for adults 
over 25 years old, not necessarily just those with neurogenic bladder, was $65.9 billion. 
Direct costs are the main driver of the overall cost of UUI in the United States, and the 
personal costs were significant 22.
Surveillance
Surveillance of patients with neurogenic bladder is intended to monitor for the common 
sequelae of neurogenic bladder, most notably urinary tract infection, upper tract 
deterioration, stones, and malignancy. Malignancy in neurogenic bladder, although rare, 
does carry a higher likelihood than in those with normal bladder function because of chronic 
catheterization, frequent UTIs, and stone disease.23 Additionally, due to the need for 
intermittent catheterization, frequent introduction of bacteria into the urinary tract combined 
with urine stasis from incomplete emptying can predispose to urinary tract infection. There 
is a balance that is struck between the detection and overtreatment of asymptomatic 
bacteriuria versus the potential for the progression to bacteremia and sepsis. Both extremes 
have potential to increase the cost burden for such patients, and as such it is recommended 
that physicians discuss the pros and cons of each strategy with their patients.
Recommendations for the care and surveillance of neurogenic bladder vary based on the 
cause of the condition as well as how long neurogenic symptoms have been present. 
Although guidelines do exist for the care and surveillance of patients with neurogenic 
bladder,3• an optimal follow-up schedule has not been definitively agreed upon. The 2012 
American Urologic Association Joint Guideline on Urodynamics makes 5 recommendations 
specific to neurogenic bladder 24. The recommendations are:
1. A post void residual assessment initially and “as part of ongoing follow up as 
appropriate”
Flack and Powell Page 5









2. An initial cystometrogram (CMG) and “as part of ongoing follow up as 
appropriate”
3. An initial pressure flow study (PFS) and “as part of ongoing follow up as 
appropriate”
4. Videourodynamics with fluoroscopy and “as part of ongoing follow up as 
appropriate”
5. An EMG in combination with CMG and “as part of ongoing follow up as 
appropriate”
For victims of spinal cord injury specifically, a 2011 review of recommendations for 
primary care physicians suggests initial evaluation of these patients should include 
urinalysis, urine culture and sensitivity, serum blood urea nitrogen/creatinine, creatinine 
clearance, and urodynamics.25 Follow up of these patients includes urinalysis and ultrasound 
every six months, urine culture whenever symptoms occur, urologic follow-up yearly, and 
urodynamic evaluation every 1-2 years.26• For those patients using intermittent self-
catheterization, many urologists advocate for regular cystoscopy and random and targeted 
bladder biopsies in addition to regular urine cytology.7•• Office copays, laboratory analysis, 
imaging, and treatment - even when covered by insurance carries intangible costs. Care 
often require time missed from work for either the patient or their caregiver, in addition to 
associated copays. Nevertheless, patients with neurogenic bladder represent heavy users of 
the healthcare system. Indeed, Manack et al. report that 40% of these patients attend at least 
one urology visit over 1 year and 33% were hospitalized during that time1•.
Although patients with OAB typically utilize less care per year than patients suffering from 
neurogenic bladder, practice patterns that impact the cost of OAB likely impact the cost of 
neurogenic bladder in a similar way. One European study utilized data from the Prospective 
Urinary Incontinence Research study, specifically looking at cost of treatment in Germany, 
Spain and the UK/Ireland. Investigators combined health insurance cost estimates with 
individual cost for pads and other treatments and noted that practice patterns varied 
significantly by country. In the UK treatment was most often administered by general 
practitioners, while in Germany and Spain patients were more likely to have consulted a 
specialist. This pattern was associated with Mean total urinary incontinence-related costs per 
patient per year ranging from €359 in the UK/Ireland to €515 in Germany and €655 in 
Spain, suggesting that access to a specialist increases cost. Quality of life and patient 
satisfaction were not investigated 27.
CONCLUSION
The costs associated with neurogenic bladder appear to be greater than those associated with 
non-neurogenic OAB. Direct costs are not easy to calculate in any region, even regions that 
participate in government-sponsored healthcare, making estimates and models important 
surrogates for determining cost of care. As cost awareness takes a more prominent role in 
healthcare worldwide more transparency in healthcare expenditures and actual 
reimbursement will be called for. Regional differences will appear. The clinician will 
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undoubtedly be asked to play a role in cost-containment, and it benefits clinicians to educate 
themselves about the relative costs of the treatments they recommend.
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